Sign In
Buy KALA
$3.54
-0.0700 (-1.94%)
At Close: Jun 22, 2026
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
04:01pm, Tuesday, 21'st Sep 2021
WATERTOWN, Mass., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement award
Kala Pharmaceuticals to Present at Upcoming Investor Conferences in September 2021
08:00am, Tuesday, 07'th Sep 2021
WATERTOWN, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization
4 Short Squeeze Penny Stocks To Watch After SPRT Stock's 1,309% Run
11:22am, Friday, 27'th Aug 2021
The SPRT stock breakout has shed light on other short-squeeze penny stocks The post 4 Short Squeeze Penny Stocks To Watch After SPRT Stock's 1,309% Run appeared first on Penny Stocks to Buy, Picks, Ne
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
04:01pm, Wednesday, 18'th Aug 2021
WATERTOWN, Mass., Aug. 18, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards
Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q2 2021 Results - Earnings Call Transcript
02:48pm, Thursday, 05'th Aug 2021
Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q2 2021 Results - Earnings Call Transcript
Kala Pharmaceuticals to Report Second Quarter 2021 Financial Results and Host Conference Call
08:00am, Thursday, 29'th Jul 2021
WATERTOWN, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative ther
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
04:01pm, Monday, 19'th Jul 2021
WATERTOWN, Mass., July 19, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
04:01pm, Friday, 18'th Jun 2021
WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Comp
Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q1 2021 Results - Earnings Call Transcript
01:31pm, Wednesday, 05'th May 2021
Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q1 2021 Results - Earnings Call Transcript
Kala Pharmaceuticals (KALA) Reports Q1 Loss, Misses Revenue Estimates
09:24am, Wednesday, 05'th May 2021
Kala Pharma (KALA) delivered earnings and revenue surprises of 3.92% and -10.28%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Kala Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
07:01am, Wednesday, 05'th May 2021
WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for disease
Kala Pharmaceuticals Has Good Short- And Long-Term Prospects
02:07am, Sunday, 25'th Apr 2021
Kala Pharmaceuticals' Eysuvis, a corticosteroid-based drug, was approved for both signs and symptoms of dry eye disease last year and sale calls began on Jan 4th 2021. The market uptake of Eysuvis has
Kala Pharmaceuticals: Eye Treatment Specialist With Much To Prove May Have Just The Product
03:52pm, Saturday, 24'th Apr 2021
Kala Pharmaceuticals has had a torrid time growing sales of its first approved ocular therapy Inveltys, for postoperative pain, which earned just $6.1m in FY20. In October last year, Kala won approval
Kala Pharmaceuticals to Present at Upcoming Investor Conferences in March
08:00am, Tuesday, 02'nd Mar 2021
WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for disease
Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q4 2020 Results - Earnings Call Transcript
02:12pm, Thursday, 25'th Feb 2021
Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q4 2020 Results - Earnings Call Transcript
